The Latest Breaking News from Vaccine

In a telephone interview with Reuters, WTO's Director-General Ngozi Okonjo-Iweala, an agreement on waiving intellectual property rights for COVID-19 vaccines is within reach. A key World Trade Organization (WTO) meeting is scheduled next week to discuss the COVID-19 vaccine patent waiver debate. "If we get one or two deliverables, that…

Early trial results suggest personalised vaccines could stop deadly disease returning

An international agreement on waiving intellectual property rights for COVID-19 vaccines is within reach ahead of a global trade meeting next week, the head of the World Trade Organization said on Wednesday.

Pancreatic cancer claims 10,000 lives in the UK each year and is the most deadly form of common cancer, with nine out of 10 patients dying within two years of diagnosis

WASHINGTON — Novavax Inc.’s coronavirus vaccine won the support of a panel of U.S. government advisers, paving the way for authorization of another tool to fight the coronavirus.

With three COVID-19 vaccines already authorized by the U.S. Food and Drug Administration, Americans have easy access to plenty of shots.

Novavax, Inc. (NASDAQ: NVAX) announced the U.S.

Novavax’s (NASDAQ: NVAX) COVID-19 vaccine (NVX-CoV2373) receives positive vote from U.S. Food and Drug Administration Vaccines and Related Biological Products Advisory Committee (VRBPAC), recommending FDA to grant Emergency Use Authorization (EUA) for individuals aged 18 years and over.

Advisers to the Food and Drug Administration overwhelmingly voted to recommend that it authorize Novavax's two-dose vaccine against COVID-19.

Officials said Novavax could fill an unmet need because there aren't non-mRNA COVID vaccines that can serve as first line defenses.

A more traditional kind of COVID-19 vaccine has moved a step closer to the U.S. market